Andrew Boulos, DO
Pulmonary Disease · Colorado Springs, CONPI 1689010100
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,623 of the $14,143 with a category attached, or 68.0%. 41 manufacturers reported payments, led by Pulmonx Corporation at 39.5% of the total.
Across 409 payments — averaging $34.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$6K
- Grifols USA, LLC$1K
- AstraZeneca$1K
- Sanofi$959
- Boehringer Ingelheim$693
- GSK$610
- plus $4K from 35 others
What the payments were for
- Consulting fees$3,20023%
- Travel & lodging$1,1188%
- Food & beverage$9,62368%
- Education$2011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$5,437
- CHARTIS CATHETER$4,107
- ZEPHYR DELIVERY CATHETER$4,107
- PULMONX CHARTIS TABLET CONSOLE$4,107
- Prolastin-C Liquid$152
- Inspire$143
- ORENITRAM$111
- TYVASO$111
- REMODULIN$111
- FLOWTRIEVER CATHETER, S$109
- CT THROMBECTOMY SYSTEM KIT$109
How this compares
$14,143 in reported general payments places this provider in the 80th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 27 | $389,904 |
| UptraviSelexipag | 12 | $262,130 |
| OpsumitMacitentan | 11 | $138,078 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $85,389 |
| Spiriva RespimatTiotropium Bromide | 82 | $51,235 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $23,292 |
| EliquisApixaban | 21 | $12,082 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,610 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,584 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,346 |
| Roflumilast | 11 | $2,155 |
| Ventolin HfaAlbuterol Sulfate | 32 | $1,883 |
| Montelukast Sodium | 97 | $800 |
| Omeprazole | 27 | $487 |
| Prednisone | 61 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $693 | $464,431155 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $212 | $400,20923 claims |
| GSKTrelegy Ellipta | $610 | $85,38998 claims |
| PfizerEliquis | $128 | $12,08221 claims |
| AstraZenecaSymbicort | $1,147 | $4,61015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Colorado Springs
- Christopher MerrickColorado Springs$34K
- Lalith UragodaColorado Springs$12K
- Russell LeeColorado Springs$11K
- Dheeraj DhotreColorado Springs$9K
- Timothy RummelColorado Springs$8K
- Yogesh ShresthaColorado Springs$7K
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
- Vamsi GunturDenver$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.